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PRC were correlated to reference methods.  Results: In 6 pa-
tients, the PAC/PRC ratio could be determined and showed 
constantly decreased values <1 (pmol/l)/(mU/l). In 2 pa-
tients, renin was noted as plasma renin activity (PRA). PAC/
PRA ratios were also clearly decreased. The diagnosis was 
subsequently genetically confirmed in 8 patients.  Conclu-
sion: A PAC/PRC ratio <1 pmol/mU and a PAC/PRA ratio <28 
(pmol/l)/(ng/ml × h) are reliable tools to identify primary hy-
poaldosteronism in newborns and infants and help to diag-
nose this life-threatening disease faster. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Primary hypoaldosteronism is a rare inborn disorder 
due to an aldosterone synthesis defect. It is transmitted 
as an autosomal recessive trait. Usually, aldosterone 
synthase is affected, which is a terminal enzyme in the 
aldosterone biosynthetic pathway that mediates the two 
last steps in the production of aldosterone  [1] . There are 
two types of aldosterone synthase defects (ASD), both 
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 Abstract 
 Background/Aims: Primary hypoaldosteronism is a rare in-
born disorder with life-threatening symptoms in newborns 
and infants due to an aldosterone synthase defect. Diagnosis 
is often difficult as the plasma aldosterone concentration 
(PAC) can remain within the normal range and thus lead to 
misinterpretation and delayed initiation of life-saving thera-
py. We aimed to test the eligibility of the PAC/plasma renin 
concentration (PRC) ratio as a tool for the diagnosis of pri-
mary hypoaldosteronism in newborns and infants.  Meth-
ods: Data of 9 patients aged 15 days to 12 months at the time 
of diagnosis were collected. The diagnosis of primary hy-
poaldosteronism was based on clinical and laboratory find-
ings over a period of 12 years in 3 different centers in Swit-
zerland. To enable a valid comparison, the values of PAC and 
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located in the  CYP11B2 gene on chromosome 8q24.3. 
Type I (ASD I) is characterized by impaired hydroxyl-
ation of corticosterone and low concentrations of the 
metabolites aldosterone and 18-hydroxycortisone. Type 
II (ASD II) is characterized by impaired conversion of 
the 18-hydroxyl group to aldehyde and elevated 18-hy-
droxycortisone levels in combination with hypoaldoste-
ronism  [2, 3] . The clinical features, including salt wast-
ing, hypovolemia, and failure to thrive, are identical in 
both types  [1, 3, 4] . Especially in newborns and infants, 
primary hypoaldosteronism is clinically relevant and re-
quires adequate therapy as the sodium/potassium me-
tabolism is mostly regulated by aldosterone at that age. 
With complete kidney maturation, aldosterone-inde-
pendent reabsorption rises and correspondingly renin 
and aldosterone levels fall. This may explain the fact that 
symptoms in patients suffering from hypoaldosteron-
ism generally become attenuated towards the first years 
of life  [1, 3] .
 Untreated primary hypoaldosteronism leads to a life-
threatening electrolyte imbalance with hyponatremia and 
hyperkalemia in newborns and infants. Typically the cor-
tisol concentration is normal and the plasma renin con-
centration (PRC) is high, with a proportional low serum 
plasma aldosterone concentration (PAC)  [1, 3] . As PAC 
values can remain in the normal range, interpretation 
might be difficult and can lead to misdiagnosis and de-
layed initiation of life-saving treatment with fludrocorti-
sone and salt. 
 The aldosterone/renin ratio is an accepted tool to di-
agnose hyperaldosteronism in adults  [5–9] . The aim of 
our study was to proof the validity of this ratio as a diag-
nostic tool for the diagnosis of primary hypoaldosteron-
ism in newborns and infants. 
 Materials and Methods 
 Patients 
 In order to include as many patients with diagnosed primary 
hypoaldosteronism as possible, we asked all 6 departments of pe-
diatric endocrinology in Switzerland to submit data of patients 
with hypoaldosteronism. Thereby, we were able to collect data of 
9 patients who were diagnosed with hypoaldosteronism and were 
being followed by 3 different departments of pediatric endocri-
nology in Switzerland (6/9 from the University Children’s Hospi-
tal Zurich, 2/9 from the Children’s Hospital of Eastern Switzer-
land, and 1/9 from the University Hospital Lausanne). The pa-
tients were diagnosed based on clinical and laboratory results at 
an age of 15 days to 12 months during the period of 2001–2013. 
Interestingly, all patients had a migration background with ori-
gins in the Balkan region (patients 1, 2, 3, 4, 5, 6, 7, and 9) and 
Tunisia (patient 8).
 Molecular Genetic Analysis 
 In order to confirm the diagnosis genetically, all patients were 
screened for mutations in the  CYP11B2 gene after obtaining in-
formed consent. 
 DNA extraction was performed using an SOP DNA Kit (Ap-
plied Biosystems/Thermo Fisher Scientific, Waltham, Mass., 
USA)/QIAamp DNA Mini Kit (Qiagen, Venlo, The Netherlands). 
PCR amplification of the  CYP11B2  gene and Sanger sequencing of 
all 9 coding exons and the exon/intron boundaries followed an es-
tablished protocol  [10] . Primers are available upon request. Muta-
tions were designated according to the recommendations of the 
Human Genome Variation Society (HGVS) based on the reference 
sequence NM_000498.3  [11] . 
 Analytical Methods 
 As patients who were diagnosed with primary hypoaldosteron-
ism at 3 different centers in Switzerland from 2001 to 2013 were 
included, the analytic methods differed depending on the time and 
place where they were performed. In 7 patients, the PAC was mea-
sured by radioimmunoassay (RIA). In patients 2, 3, and 4, a Coat-
A-Count aldosterone RIA (Siemens, Eschborn, Germany) was 
used. In patients 6 and 7, PAC were determined using an aldoste-
rone direct RIA (DRG Diagnostics GmbH, Marburg, Germany). 
The DSL active aldosterone RIA (Diagnostic Systems Laborato-
ries, Inc./Beckman Coulter, Brea, Calif., USA) was used in patient 
1. In patient 8, the ALDO-CTK-2 RIA (DiaSorin, Saluggia, Italy) 
was used. In patient 5, the PAC was determined via chemilumines-
cence immunoassay (CLIA; DiaSorin) on a Liaison immunoana-
lyzer. To compare the aldosterone levels of the patients, the PAC 
were traced back to an automated chemiluminescence assay (Nich-
ols Advantage; Nichols Institute Diagnostics, San Clemente, Calif., 
USA) using equations from method comparison studies provided 
by DiaSorin, the laboratory of Dr. Limbach (Heidelberg, Germa-
ny), the Nichols Institute, Beckman Coulter, and K. Spanaus. The 
DRG and DSL RIA are the same assay and were being distributed 
by Beckman Coulter at the time of reporting. It was further pos-
sible to correlate Siemens Coat-A-Count aldosterone with DSL ac-
tive aldosterone (information by Beckman Coulter) and ALDO-
CTK-2 (information by DiaSorin). Liaison by  DiaSorin was cor-
related with DRG (K. Spanaus, method evaluation on the Liaison 
immunoanalyzer in comparison to the DRG RIA). Accordingly, 
we converted the values using given factors in reference to the 
DRG RIA and the DSL assay. In a second step, we correlated the 
data to an automated chemiluminescence assay (Nichols Advan-
tage) based on the correlation study by Schirpenbach et al.  [12] . 
 In patient 9, a noncommercial RIA was used based on the 
method published in 1984 by Nussberger et al.  [13] . As no correla-
tion studies for this test were available, we were not able to corre-
late these values exactly to the other methods. 
 In order to standardize the PAC values, which were document-
ed in nanograms per liter, picomoles per liter, or picograms per 
milliliter, they were converted to picomoles per liter.
 The PRC was measured by RIA in 4 patients (1, 2, 6, and 7). In 
patient 1 as well as in patient 7, a Cis Bio RIA (Schering AG, Berlin, 
Germany) was used. In patient 2, the PRC was determined using a 
Bio-Rad third-generation RIA (Bio-Rad Laboratories, Inc., Hercu-
les, Calif., USA). In patient 6, a Nichols RIA (Nichols Institute Di-
agnostics) was utilized.
 In 3 patients (3, 4 and 5), the PRC was measured via chemilu-
minescence assay. In patients 3 and 5, the DiaSorin test on a Liai-
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son immunoanalyzer was used. In patient 4, the PRC was deter-
mined via chemiluminescence assay on a Nichols Advantage  im-
munoanalyzer (Nichols Institute Diagnostics). 
 According to existent method comparison studies, it was pos-
sible to trace back the PRC of the patients to the CLIA on the Nich-
ols Advantage analyzer. Liaison, Bio-Rad, and Nichols RIA assays 
could be directly correlated to the Nichols Advantage by given 
equations provided by DiaSorin, the laboratory of Dr. Limbach 
(Heidelberg, Germany), and the Nichols Institute. The values mea-
sured by the Cis Bio RIA first needed to be correlated to the Dia-
Sorin CLIA and in a second step to the Nichols Advantage (infor-
mation by DiaSorin) as there were no direct correlation studies 
available.
 In patients 8 and 9, renin was measured as plasma renin activ-
ity (PRA). In patient 8, an RIA named RENCTK by DiaSorin was 
used. For determination of the PRA in patient 9, a radioimmuno-
logical microassay was used by Nussberger et al.  [14] , which is 
based on the method by Poulsen and Jorgensen  [15] . 
 The PRC values were noted in picomoles per liter, units per li-
ter, or nanograms per milliliter and were converted to milliunits 
per liter to enable comparison. The PAC/PRC ratio (pmol/mU) 
was calculated for each patient ( table 1 ).
 The equations used to trace back the values to the Nichols Ad-
vantage are listed in online suppl. tables 1 and 2 (for all online 
suppl. material, see www.karger.com/doi/10.1159/000381852).
 Results 
 All 9 patients showed typical laboratory features with 
hyponatremia (mean serum sodium level 123.6 mmol/l, 
range 117–132 mmol/l) at the time of diagnosis. Seven 
patients showed hyperkalemia (mean serum potassium 
level 6.1 mmol/l, range 4.6–8.4 mmol/l). Patient 9 showed 
a potassium concentration within the upper range (4.6 
mmol/l), and in patient 8 the potassium level was not
documented ( table 1 ). 
 Aldosterone and renin values were measured in all 9 
patients at the time of diagnosis. The PAC was measured 
via 3 different assays in patients 1–6. The values were cor-
related to Nichols Advantage in order to allow compari-
son of the data. In all 6 patients, the PAC was low but 
within the normal range (mean 744.5 pmol/l, range 126–
1,906 pmol/l) ( table 1 ). In these 6 patients, renin was mea-
sured as the PRC via 5 different methods. As described 
above (Materials and Methods), the values were corre-
lated to Nichols Advantage. The corrected PRC values 
were strongly elevated (mean PRC 304,895 mU/l, range 
 Table 1. Overview of patients 1–7 with laboratory values at the time of diagnosis, PAC/PRC ratios, and mutations
Patient 
No.
Age at the 
time of 
diagnosis
Sodiuma,
mmol/l
Potassiumb,
mmol/l
Corrected 
PACc, pmol/l
Corrected 
PRCd, mU/l
PAC/PRC 
ratioe, pmol/mU
Mutation
1 15 days 128 6.2 1,906 9,686 0.1968 homozygous mutation 
pThr185Ile in the CYP1182 
gene
2 4 weeks 125 6.1 217 74,423 0.0029 homozygous mutation 
pThr185Ile in the CYP1182 
gene
3 12 weeks 121 5.9 801 256,041 0.0031 homozygous mutation 
pThr185Ile in the CYP1182 
gene
4 3 months 120 8.4 947 95,258 0.0099 homozygous mutation 
pThr185Ile in the CYP1182 
gene
5 4 months 124 5.8 89 1,390,330 0.0001 heterozygoty for p.
Thr185Ile and c.2798+1 
G>A
6 2 weeks 117 6.2 470 3,634 0.1293 homozygous mutation 
pThr185Ile in the CYP1182 
gene
7 6 months 122 5.4 838 >626 <1.3387f homozygous mutation 
pThr185Ile in the CYP1182 
gene
 a Reference range 134–144 mmol/l. b Reference range 3.5–5 mmol/l. c Reference range 27.7–4,995 pmol/l. d Reference range 2.8–39.9 
mU/l. e Reference range 1–71 pmol/mU. f The PRC was given as a minimal value and therefore the PAC/PRC ratio is the highest 
assumable value.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
26
/2
01
6 
1:
54
:3
3 
PM
 Ruecker   et al.
 
 Horm Res Paediatr 2015;84:43–48 
DOI: 10.1159/000381852
46
3,634–1,390,330 mU/l) ( table 1 ). The PAC/PRC ratio was 
determined for each patient (1–6, in pmol/mU) and 
showed strongly decreased values clearly <1 pmol/mU 
(mean 0.0737 pmol/mU, range 0.0001–0.1968 pmol/mU) 
( table 1 ). 
 In all 6 patients, mutations in the  CYP11B2 gene that 
are correlated with aldosterone synthase deficiency were 
detected. In patients 1, 2, 3, 4, and 6, homozygous C-to-T 
transversion in codon 185 in the  CYP11B2 gene was 
found ( table 1 ). It causes an amino acid substitution of 
threonine by isoleucine (p.Thr185Ile). 
 Patient 5 was compound heterozygous for the
p.Thr185Ile and c.2798 + 1 G>A (IVS8 + 1 G>A) muta-
tions. The latter is located in a highly conserved area of 
the donor splice site of intron 8 of the  CYP11B2 gene
( table  1 ). It was described in connection with hypoal-
dosteronism by Merakou et al.  [16] .
 In patient 7, the diagnosis was genetically confirmed 
by detection of the homozygous mutation p.Thr185Ile in 
the  CYP11B2 gene ( table 2 ). The PRC was only noted as 
a minimal value as the material was not sufficient for di-
lution of the sample to measure the exact concentration. 
After correlating the primary values to reference meth-
ods, the resulting PAC was 838 pmol/l and the PRC was 
>626 mU/l. The maximum credible value for the PAC/
PRC ratio would be <1.3387 pmol/mU. 
 In patients 8 and 9, renin was measured as PRA. In pa-
tient 8, the PAC was given as a range and was correlated 
to the Nichols Advantage. The corrected values (172–283 
pmol/l) remained in the reference range. In contrast, the 
PRA was highly increased [i.e. 37 ng/ml × h; reference 
range 0.2–2.8 ng/ml × h (supine), 1.5–7.7 ng/ml × h (up-
right)]. The PAC/PRA ratio resulted in a decreased range 
of 4.6486–7.6486 (pmol/l)/(ng/ml × h) [reference: >28 
(pmol/l)/(ng/ml × h)]. Genetic analysis was performed 
but could not detect any mutation within the extronic 
area ( table 2 ).
 In patient 9, comparison with the other measurements 
was not possible as there were no correlation studies 
available. Nevertheless, the PRA (66 ng/ml × h) was 
strongly elevated in comparison to the provided refer-
ence range [0.2–2.0 ng/ml × h (supine), 1.5–4.5 ng/ml × h
(upright)]. The PAC was normal [i.e. 300 pmol/l; refer-
ence range 80– 11 pmol/l (supine), 166–665 pmol/l (up-
right)]. The PAC/PRA ratio was decreased [i.e. 4.5455 
(pmol/l)/(ng/ml × h)]. The diagnosis of ASD was geneti-
cally confirmed in patient 9 by detection of the homozy-
gous mutation p.Thr185Ile in the  CYP11B2 gene ( ta-
ble 2 ).
 Discussion 
 In newborns and infants, the diagnosis of primary hy-
poaldosteronism is based on clinical and laboratory re-
sults. That is how all 9 patients in this study were diag-
nosed initially. 
 Diagnosing ASD can be difficult due to the fact that 
the PAC may appear in the normal range like in all of our 
patients. In these cases the PAC/PRC ratio, which is al-
ready an accepted screening tool for hyperaldosteron-
ism, can be useful. A PAC/PRC ratio <1 pmol/mU indi-
cates an inappropriately low PAC for the stimulus. 
Therefore, a decreased aldosterone/renin ratio is sugges-
tive of hypoaldosteronism as has been shown in adults 
 [9, 17] . The benefit of using the PAC/PRA ratio to diag-
nose various disorders of the renin-angiotensin-aldoste-
rone axis was described in 1991 by McKenna et al.  [9] , 
who described subnormal PAC/PRA ratios in the con-
text of primary adrenal insufficiency in adults. In 2007, 
 Table 2. Overview of patients 8 and 9 with laboratory values at the time of diagnosis, PAC/PRC ratios, and mutations
Patient 
No.
Age at time 
of diagnosis, 
months
Sodiuma, 
mmol/l
Potassiumb, 
mmol/l
Corrected 
PACc,
pmol/l
Corrected 
PRAd, 
ng/ml × h
PAC/PRA 
ratioe, (pmol/l)/
(ng/ml × h)
Mutation
8 3 123 NA 172–283f 37 4.6486–7.6486 no mutation found
9 24 132 4.6 300 66 4.5455 homozygous mutation 
pThr185Ile in the CYP1182 
gene
a Reference range 134–144 mmol/l. b Reference range 3.5–5 mmol/l. c Reference range 27.7–4,995 pmol/l. d Reference range 0.2–7.7 
ng/ml × h. e Reference range >28 (pmol/l)/(ng/ml × h). f The PAC was given as a range and therefore the PAC/PRA was also calculated 
as a range.
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Diederich et al.  [17] revolutionized the approach by us-
ing the PRC instead of the PRA as the PRC became the 
international standard to measure renin values. A sub-
normal PAC/PRC ratio <1 pmol/mU (reference range 
1–72 pmol/mU) was found in 14 adults with primary hy-
poaldosteronism mostly due to adrenal insufficiency. 
Based on our study of 9 newborns and infants with aldo-
sterone synthase deficiency, the PAC/PRC ratio (pmol/
mU) seems to be a reliable diagnostic parameter in this 
age group as well ( table  1 ). The pathophysiology, of 
course, differs in adults with primary adrenal insufficien-
cy compared to infants and newborns with ASD, but the 
hormone constellation with a high PRC and a low PAC 
is the same. 
 Based on correlation studies, we were able to correlate 
PAC and PRC to a reference method in 7 patients (1–7). 
In these patients, PAC and PRC values were correlated to 
Nichols Advantage (Material and Methods) as this was 
the method used by Diederich et al.  [17] , who suggested 
a PAC/PRC ratio <1 pmol/mU as a predictor of primary 
hypoaldosteronism in adults. 
 In 6 patients (1–6), the PAC/PRC ratio was clearly <1 
pmol/mU (mean 0.0737 pmol/mU) even though the PAC 
values remained within the normal range, as is typical for 
ASD II. 
 In 5 (patients 1, 2, 3, 4, and 6) of these 6 patients the 
diagnosis was genetically confirmed by detection of the 
well-known homozygous p.Thr185Ile mutation, which is 
correlated with ASD II  [18, 19] . Patient 5 was compound 
heterozygous. The well-known p.Thr185Ile mutation was 
found here as well in the heterozygote form. The second 
mutation c.2798 + 1 G>A (IVS8 + 1) lies within the donor 
splice site of intron 8 of the  CYP11B2 gene. This com-
pound-heterozygous mutation was described in connec-
tion with hypoaldosteronism by Merakou et al.  [16] ( ta-
ble 1 ). 
 In patient 7, the PRC was only noted as a minimal val-
ue as the material was not sufficient for serial dilution 
analysis to determine the exact value. Therefore, the exact 
PAC/PRC ratio could not be determined. 
 In patients 8 and 9, renin was noted as PRA, which 
could not be correlated to PRC as no correlation studies 
for the used methods were available. Due to the fact that 
nanograms per milliliter × hour could not be converted 
into milliunits per liter, a direct comparison was not pos-
sible. Based on McKenna et al.  [9] , who used the PAC/
PRA ratio as a diagnostic tool and associated values <28 
(pmol/l)/(ng/ml × h) with hypoaldosteronism, the pa-
tients fulfilled this criterion as well. Both patients showed 
PAC/PRA ratios which were clearly lower than 28 
(pmol/l)/(ng/ml × h) [patient 8: 4.6486–7.6486 (pmol/l)/
(ng/ml/h), patient 9: 4.5455 (pmol/l)/(ng/ml × h)]. It is 
most likely that a PAC/PRC ratio measured in these pa-
tients (8 and 9) would have been <1 pmol/mU, too. 
 It is suspicious that 7 (patients 1, 2, 3, 4, 6, 7 and 9) of 
our 9 patients showed the same homozygous mutation 
(p.Thr185Ile). Even though patients 3 and 4 are second 
cousins to each other, we did not find any other family 
relationship between these study patients. Moreover, di-
rect consanguinity could have been excluded within all of 
these families over 3 generations (see online suppl. fig. 1, 
2, 3, 5, 6, and 8 showing the pedigree of patients 1, 2, 3, 4, 
6, 7, and 9). It is conspicuous that 5 of these families be-
long to an ethnic minority group (i.e. Catholic Kosovo 
Albanian: patients 3, 4, and 7; Catholic Serb: patient 6, 
and Muslim Macedonian: patient 2). Moreover, the re-
maining patients (1 and 9) with the homozygous muta-
tion also originated from the Balkan region (Macedonia 
and Albania). Due to this fact, we presume a founder
effect. 
 Interestingly, in patient 8 no mutation was detected. 
Assuming the parents were cousins to each other, it is 
presumable that this patient is homozygous for a muta-
tion, which could not been detected by the genetic analy-
sis used (see online suppl. fig. 7 showing the pedigree of 
patient 8).
 In summary, the data of our patients along with the 
given aldosterone and renin values strongly indicate 
that a PAC/PRC ratio <1 pmol/mU is a reliable marker 
to diagnose ASD in newborns and infants. Thus, we are 
convinced that the PAC/PRC ratio is a feasible and cost-
saving tool for the diagnosis of primary hypoaldoste-
ronism in this age group. We recommend using the 
PAC/PRC ratio in infants and newborns who present 
with the typical electrolyte constellation and clinical
signs of hypoaldosteronism to verify the diagnosis. The
PAC/PRC ratio can help to diagnose this life-threaten-
ing disease faster and consequently initiate life-saving 
therapy earlier.
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